Roman G. Plavnik

Roman G. Plavnik

Auto-generated profile, based on publicly available information

Roman G. Plavnik

ISOCARB LLC

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

15 August 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
MAMaria D. Ardatskaya
Maria D. Ardatskaya
LBLudmila I. Butorova
Ludmila I. Butorova
MKMarina A. Kalashnikova
Marina A. Kalashnikova
NNNelli R. Nugaeva
Nelli R. Nugaeva
YOYury V. Ovchinnikov
Yury V. Ovchinnikov
ТБТопчий Татьяна Борисовна
Топчий Татьяна Борисовна
Background. The novel coronavirus infection COVID-19 can be manifested by damage to the organs of the gastrointestinal tract (GIT). Damage to the gastrointestinal tract by the SARS-CoV-2 virus leads to a violation of the microbial-tissue complex of the mucous membrane of the digestive tract. A common gastroenterological manifestation of COVID-19 is diarrhea. Aim. Study of the clinical features of gastroenterological disorders and the possibility of optimizing the treatment of diarrheal syndrome in patients with COVID-19 with a mild form of viral infection. Materials and methods. The observation group consisted of 230 patients with mild COVID-19: K-group (n=115) with respiratory symptoms, I group (n=115) with gastrointestinal manifestations in combination and without signs of respiratory damage. In order to compare the effectiveness of treatment of diarrheal syndrome, patients of group I are randomized into 2 subgroups: Ia (n=58) prebiotic treatment (Zacofalk) and Ib (n=57) enterosorbents. Results. The development of gastrointestinal symptoms with SARS-CoV-2 infection is significantly more often noted in comorbid patients (67%). Gastrointestinal symptoms were dominated by diarrhea (93.9%) and flatulence (76.5%), in 1/3 of patients they were the first manifestos of infection. It was established that in 98.4% of patients of group I (against 42.6% of the K-group) signs of infectious intoxication were detected. In patients with gastrointestinal lesions, an elongation of the febrile period by 91.5 days was noted, a later (6 days) verification of the viral etiology of the disease. It was found that in patients of group I, the regression of clinical symptoms, the duration of viral disease, the dynamics of antibody formation, the prognosis for the development of IBS-like disorders in the post-infectious period depended on the treatment. In patients taking (Zacofalk), these indicators were significantly better. Conclusion. In mild cases, to reduce the severity of viral intestinal damage, for effective relief of intestinal symptoms, to reduce the risk of IBS-like symptoms, it is advisable to prescribe (Zacofalk) in an initial dose of 3 tablets per day.

19 April 2020 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
LBL. I. Butorova
L. I. Butorova
MAM. D. Ardatskaya
M. D. Ardatskaya
MOMikhail A. Osadchuk
Mikhail A. Osadchuk
NKN. G. Kadnikova
N. G. Kadnikova
ELE. I. Lukianova
E. I. Lukianova
ТМТуаева Елена Михайловна
Туаева Елена Михайловна
Low patient compliance due to the development of adverse events in the form of antibiotic-associated diarrhea (AAD) is considered as the main reason for the failure of the eradication of optimized anti-Helicobacter therapy regimens. A key mechanism for the development of AAD is to reduce the number and species diversity of bacteria that form butyric acid. Aim. The purpose of this study was to study the comparative effect on the clinical effectiveness of eradication therapy (ET) of Helicobacter pylori infection and metabolic changes in the colon microbiota of additional inclusion in the optimized treatment regimen of the combined prebiotic Zakofalk (inulin + butyrate) with probiotics (lacto- and bifidobacteria in an amount of at least 1017 СFU). Materials and methods. 120 patients with chronic gastroduodenal diseases and infected H. pylori were еxamined. A comparative analysis of the effect of a combined prebiotic and lacto-bifid-containing probiotics on improving the effectiveness of the optimized ET scheme and improving its tolerability, as well as on the quantitative and qualitative content of short-chain fatty acids (SFA) in feces. The success of eradication was controlled by a 13C urease breath test. Results. According to the results of the study in randomized groups of patients, an excellent percentage of eradication (95%) was achieved in patients who performed ET with the addition of the prebiotic Zakofalk. In the same group of patients, there was an increase in the absolute content of SFA and a significant increase in the concentration of butyric acid. In the group of patients who received ET with the addition of probiotics, an acceptable level of eradication was achieved (85.7%), but no changes in SFA were found indicating an increase in the number or activity of the butyrate-producing flora. Patients who performed ET without the addition of pre-probiotics did not achieve the target percentage of successful eradication (83.3%), and a significant quantitative decrease in SFA was found with a significant decrease in the proportion of butyric acid. Conclusion. The inclusion of Zakofalk in the ET scheme, in comparison with probiotics, significantly increases the probability of successful eradication, more effectively restores the metabolic potential of the microbiota, and prevents the development of AAD.

3 September 2020 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
LBL. I. Butorova
L. I. Butorova
MAM. D. Ardatskaya
M. D. Ardatskaya
MOMikhail A. Osadchuk
Mikhail A. Osadchuk
ADA. E. Drobysheva
A. E. Drobysheva
EZE. A. Zagrebina
E. A. Zagrebina
ТМТуаева Елена Михайловна
Туаева Елена Михайловна
In the clinical classification of cholelithiasis, biliary sludge (BS) is distinguished as the pre-stone stage. Ursodeoxycholic acid (UDCA) is a drug with an evidence base for effective and safe effects on BS. The therapeutic equivalence of various UDCA drugs remains an important issue for clinical practice. Aim. To conduct a comparative analysis of the effectiveness of the use of UDCA: Ursofalk with other UDCA drugs for the treatment of BS in a fixed dose of 10 mg/kg of body weight. Material and methods. The observation group consisted of 225 patients with various types of BS. In randomized groups, the comparison of the effectiveness of UDCA drugs in the dissolution of BS was determined by the data of ultrasound of the gallbladder. Dynamic ultrasound cholecystography using a standardized technique was performed to study the effect of the compared drugs on the contractile function of the liver. When analyzing the impact of ursotherapy on the clinical manifestations of BS, the dynamics of biliary pain syndrome and dyspeptic disorders were evaluated. Results. A comparative analysis of the effectiveness of UDCA drugs for BS lysis with a high degree of confidence established the advantage of Ursofalk: after 3 months in 80%, and after 6 months of therapy in 95.65% of patients, a regression of BS was detected. In the group of patients who took other UDCA, the corresponding indicators were 46.36% and 67.27%. The greatest effectiveness of ursotherapy was demonstrated in the BS variant by the type of suspension of hyperechogenic particles, the lowest in the variant by the type of putty-like bile in the form of mobile or fixed clots. In the last variant of BS, the relationship between the success of lysis with the extension of the UDCA intake period to 6 months and the preferred choice of Ursofalk was traced. Normalization of the contractile function of the gallbladder was noted in patients who took Ursofalk. Conclusion. From the standpoint of therapeutic effectiveness, the drug of choice for the treatment of BS, regardless of its type, is Ursofalk, which has proven the best dynamics of BS litolysis, recovery of the contractile function of the gastrointestinal tract, and relief of clinical symptoms.

28 May 2020 in HERALD of North-Western State Medical University named after I.I. Mechnikov
Verified
Journal Article
Open access
PDF file
RPRoman G. Plavnik
Roman G. Plavnik
VNVassiliy I. Nevmerzhitsky
Vassiliy I. Nevmerzhitsky
LBLudmila I. Butorova
Ludmila I. Butorova
NBNatalia V. Bakulina
Natalia V. Bakulina
НИНевмержицкий Василий Иванович
Невмержицкий Василий Иванович
The article presents the data and review of the North American Consensus (2017) recommendations on the use of hydrogenmethane breathing test in diagnosing gastrointestinal disorders accompanied by excessive bacterial growth in the small intestine. On May 16, 2015, 17 leading scientists specializing in breathing tests took part in a consensus meeting in Washington (DC, USA). By a voting method, 28 consensus statements were identified and recommendations were given on the following issues regarding the use of the hydrogen-methane the procedure itself test in gastroenterological practice: 1) preparation for a breathing test; 2) indications for a breathing test; 3) the procedure itself; 4) interpretation of results; 5) gaps in the knowledge and unresolved issues.

14 January 2022 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
RPR. G. Plavnik
R. G. Plavnik
ETE. V. Tivanova
E. V. Tivanova
VNV. I. Nevmerzhitskiy
V. I. Nevmerzhitskiy
TPT. E. Plavnik
T. E. Plavnik
LGL. I. Gubaydulina
L. I. Gubaydulina
TBT. A. Batyukhno
T. A. Batyukhno
The Small Intestine Bacterial Overgrowth syndrome ( SIBO) is a widespread pathology both independently and in combination with other diseases of the gastrointestinal tract, therefore, its timely and accurate diagnosis remains a very urgent task.Aim. Purpose of the study: comparative assessment of the diagnostic information content of two methods for diagnosing SIBO—hydrogen-methane breath test (HMBT) and stool analysis for short-chain fatty acids (SCFA).Material and Methods: 65 patients aged from 18 to 76 years were examined. 40 made up the main group, with clinical symptoms of SIBO, and 25—the control group. All patients underwent HMBT with the «SIBRTEST» test kit and stool analysis for SCFA. For both tests, diagnostic sensitivity, specifi city, and accuracy were calculated and comparatively evaluated.Results: HMBT showed sensitivity 90.24%, specifi city 95.83%, accuracy 92.3%. The analysis of feces for SCFA showed, respectively, a sensitivity of 90.24%, a specifi city of 50.0% and an accuracy of 75.38%.Conclusion: HMBT with the SIBRTEST test kit can be recommended in the diagnosis of SIBO. The SCFA test should be treated with caution due to the high probability of false positive results.